NFNathaniel Fleming

Nathaniel Fleming

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathaniel Fleming has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Social Determinants of Health in Early to Mid-Adulthood and Risk of Early-Onset Stroke

    by Nathaniel H. Fleming, Christina S. Dintica, Alexander Arynchyn, Donald M. Lloyd-Jones, Daniel T. Lackland, Kristine Yaffe

    BACKGROUND: Despite increasing incidence of stroke among younger adults, the associations of social determinants of health (SDOH) and stroke among younger adults are not well known. This study investigates the associations between SDOH from early adulthood and stroke in a prospective longitudinal cohort. METHODS: We studied participants enrolled in the CARDIA study (Coronary Artery Risk Development in Young Adults). Participants aged 18 to 30 years were enrolled in 1985 and followed through 2022. We investigated longitudinal, time-varying measures of SDOH classified into 5 distinct domains: economic (6 measures), education (1 measure), healthcare (4 measures), neighborhood (2 measures), and social/community (5 measures). The outcome was incident stroke or transient ischemic attack. We evaluated associations between individual SDOH and stroke using unadjusted Cox models. We then evaluated whether a greater cumulative number of adverse SDOH domains (each represented by 1 exposure selected by empirical techniques) was associated with stroke risk after adjustment for demographics. RESULTS: Among the 5114 participants (54.5% were female; baseline age, 25 years; and median follow-up, 37.9 years), 146 individuals experienced stroke or transient ischemic attack, all of which occurred P trend =0.005). In interaction analyses, the association between income and stroke appeared stronger in Black participants ( P interaction =0.02) and women ( P interaction =0.02). CONCLUSIONS: In this young cohort followed through midlife, SDOH spanning several domains were associated with stroke risk. We also observed a dose-dependent response with the number of adverse SDOH domains experienced. Our results suggest that SDOH experienced throughout adulthood are relevant to future stroke risk.

  • Open Access

    Risk of dementia in older veterans with multiple sclerosis

    by Nathaniel H Fleming, Amber Bahorik, Feng Xia, Kristine Yaffe


  • Chapter 9: Sleep Medicine

    by Nathaniel H. Fleming, Liza Ashbrook

  • Open Access

    Supplementary Tables 1 - 5 from PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition

    by Heidi L. Gold, Jordan Wengrod, Eleazar Vega-Saenz de Miera, Ding Wang, Nathaniel Fleming, Lisa Sikkema, Tomas Kirchhoff, Tsivia Hochman, Judith D. Goldberg, Iman Osman, et al.

  • Open Access

    Supplementary Tables 1 - 5 from PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition

    by Heidi L. Gold, Jordan Wengrod, Eleazar Vega-Saenz de Miera, Ding Wang, Nathaniel Fleming, Lisa Sikkema, Tomas Kirchhoff, Tsivia Hochman, Judith D. Goldberg, Iman Osman, et al.

    PDF file - 151K, Supplemental Table 1. mutations found in NYU cohort and previously discovered by Hodis et al; and Krauthammer et al; Supplemental Table 2. Breslow-Day test of homogeneity for association between PP6C, BRAF, or NRAS mutations in Primary and Metastatic patients respectively. Supplemental Table 3. Bbaseline characteristics and prognostic factors by PP6C mutation status in primary and metastatic patients. Supplemental Table 4: PP6C, BRAF and NRAS mutation allele:wild-type allele ratios. Supplemental Table 5. Correlation of PP6R binding and Aurora A Kinase phosphorylation(primary patients only).

  • TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors

    by Gregory A. Chang, Jennifer M. Wiggins, Broderick C. Corless, Mahrukh M. Syeda, Jyothirmayee S. Tadepalli, Shria Blake, Nathaniel Fleming, Farbod Darvishian, Anna Pavlick, Russell Berman, et al.


  • Open Access

    Impact of primary care provider density on detection and diagnosis of cutaneous melanoma

    by Nathaniel H Fleming, Madeline M Grade, Eran Bendavid

    Early diagnosis of cutaneous melanoma is critical in preventing melanoma-associated deaths, but the role of primary care providers (PCPs) in diagnosing melanoma is underexplored. We aimed to explore the association of PCP density with melanoma incidence and mortality. All cases of cutaneous melanoma diagnosed in the United States from 2008–2012 and reported in the Surveillance, Epidemiology, and End Results (SEER) database were analyzed in 2016. County-level primary care physician density was obtained from the Area Health Resources File (AHRF). We conducted multivariate linear regression using 1) average annual melanoma incidence or 2) average annual melanoma mortality by county as primary outcomes, adjusting for demographic confounders and dermatologist density. Cox proportional hazard regression was conducted using individual outcome data from SEER with the same covariates. Across 611 counties, 167,305 cases of melanoma were analyzed. Per 100,000 people, an additional 10 PCPs per county was associated with 1.62 additional cases of melanoma per year (95% CI 1.06–2.18, p<0.001). This increased incidence occurred disproportionally in early-stage melanoma (Stage 0: 0.69 cases (0.38–1.00), p<0.001; Stage I: 0.63 cases (0.37–0.89), p<0.001; Stage II: 0.11 cases (0.03–0.19), p = 0.005). There was no statistically significant association between PCP density and incidence of stage III or IV melanoma, or with melanoma-specific mortality. Survival analysis demonstrated elimination of 5-year post-diagnosis mortality risk in medically underserved counties after adjusting for stage. Higher densities of PCPs may be linked to increased diagnosis of early-stage melanoma without corresponding decreases in late-stage diagnoses or melanoma-associated mortality.